Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Noscapine | 5 | 2014 | 17 | 0.650 |
Why?
|
| Lung Neoplasms | 10 | 2014 | 479 | 0.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2011 | 130 | 0.610 |
Why?
|
| Antineoplastic Agents | 9 | 2014 | 979 | 0.350 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 134 | 0.260 |
Why?
|
| Indoles | 3 | 2013 | 178 | 0.230 |
Why?
|
| Haloperidol | 3 | 2012 | 36 | 0.190 |
Why?
|
| Caspase 3 | 5 | 2011 | 226 | 0.190 |
Why?
|
| Apoptosis | 8 | 2011 | 1541 | 0.180 |
Why?
|
| Taxoids | 4 | 2013 | 50 | 0.180 |
Why?
|
| Azepines | 2 | 2012 | 22 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2013 | 339 | 0.160 |
Why?
|
| Mice, Nude | 6 | 2013 | 403 | 0.160 |
Why?
|
| Mice | 15 | 2014 | 6490 | 0.160 |
Why?
|
| Antipsychotic Agents | 2 | 2012 | 81 | 0.160 |
Why?
|
| Drug Synergism | 5 | 2011 | 189 | 0.150 |
Why?
|
| Pyrazoles | 3 | 2010 | 93 | 0.140 |
Why?
|
| Sulfonamides | 3 | 2010 | 88 | 0.140 |
Why?
|
| Antitussive Agents | 2 | 2014 | 7 | 0.130 |
Why?
|
| Animals | 18 | 2014 | 16695 | 0.130 |
Why?
|
| Lung | 4 | 2014 | 484 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2014 | 458 | 0.110 |
Why?
|
| Annexin A2 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Intestinal Absorption | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cell Line, Tumor | 8 | 2014 | 2598 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 137 | 0.100 |
Why?
|
| Anisoles | 1 | 2013 | 3 | 0.100 |
Why?
|
| Benzoates | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cell Survival | 3 | 2013 | 934 | 0.100 |
Why?
|
| Losartan | 1 | 2013 | 35 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 41 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 94 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 246 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 209 | 0.100 |
Why?
|
| Phenols | 1 | 2013 | 102 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 436 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2011 | 35 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 62 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 78 | 0.090 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.080 |
Why?
|
| Bromocriptine | 1 | 2010 | 6 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 95 | 0.080 |
Why?
|
| Nanoparticles | 2 | 2013 | 449 | 0.080 |
Why?
|
| Cisplatin | 1 | 2010 | 91 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 2012 | 369 | 0.080 |
Why?
|
| Butyrophenones | 1 | 2008 | 8 | 0.070 |
Why?
|
| Female | 12 | 2013 | 24018 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 76 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.070 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 26 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2007 | 50 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2007 | 55 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2014 | 1737 | 0.060 |
Why?
|
| Administration, Inhalation | 3 | 2013 | 92 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 228 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 34 | 0.060 |
Why?
|
| Caco-2 Cells | 2 | 2014 | 59 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2014 | 84 | 0.050 |
Why?
|
| Ionophores | 1 | 2003 | 11 | 0.050 |
Why?
|
| Rats | 4 | 2014 | 3701 | 0.050 |
Why?
|
| Monensin | 1 | 2003 | 4 | 0.050 |
Why?
|
| Immunotoxins | 1 | 2003 | 13 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 2007 | 98 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 506 | 0.050 |
Why?
|
| Biological Availability | 2 | 2014 | 115 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 180 | 0.040 |
Why?
|
| Humans | 11 | 2014 | 42163 | 0.040 |
Why?
|
| DNA Fragmentation | 2 | 2011 | 95 | 0.040 |
Why?
|
| Lipids | 2 | 2014 | 256 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1679 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 160 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2014 | 1617 | 0.040 |
Why?
|
| Aerosols | 2 | 2010 | 53 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2010 | 151 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2009 | 129 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2010 | 560 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 928 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 138 | 0.030 |
Why?
|
| Dinoprostone | 2 | 2006 | 69 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 134 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 201 | 0.030 |
Why?
|
| Permeability | 1 | 2013 | 66 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 385 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 933 | 0.020 |
Why?
|
| Collagen | 1 | 2013 | 178 | 0.020 |
Why?
|
| Neoplasms | 1 | 2003 | 1341 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 26 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 111 | 0.020 |
Why?
|
| Male | 4 | 2014 | 22779 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 2012 | 68 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 290 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 117 | 0.020 |
Why?
|
| Pyridines | 1 | 2012 | 134 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 10 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 55 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 4 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 127 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2010 | 93 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 884 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1112 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 238 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 267 | 0.020 |
Why?
|
| Apomorphine | 1 | 2008 | 14 | 0.020 |
Why?
|
| Clozapine | 1 | 2008 | 17 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 32 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 23 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 273 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 686 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 355 | 0.020 |
Why?
|
| Nanostructures | 1 | 2010 | 158 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 711 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 491 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 65 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 74 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 649 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1420 | 0.010 |
Why?
|
| Brain | 1 | 2012 | 1452 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 287 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 158 | 0.010 |
Why?
|
| Liposomes | 1 | 2003 | 130 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 2111 | 0.010 |
Why?
|